Factors associated with time lag between symptom onset and reporting in the first epidemic wave of COVID-19 in Osaka, Japan

Takeshi Miyama*, Kensaku Kakimoto, Nobuhiro Iritani, Kazushi Motomura

Authors' affiliation: Division of Public Health, Osaka Institute of Public Health, 1-3-69 Nakamichi, Higashinari-ku, Osaka City, Osaka 537-0025, Japan

ARTICLE INFO

Keywords: COVID-19 Japan reporting lag risk factor first epidemic wave

ABSTRACT

Objectives: Longer reporting lags after symptom onset reportedly exert a substantial impact on onward transmission, increasing outbreak probability. Our study investigated the risk factors associated with reporting lag.

Methods: Using active epidemiological surveillance data for all symptomatic cases reported in Osaka Prefecture during the first wave of the coronavirus disease 2019 (COVID-19) epidemic (February 1–May 13, 2020), multi-variable regression analyses were implemented to estimate the effects of exposure variables on reporting lag, by controlling for potential confounders.

Results: Cases in their 30s showed a longer reporting lag than cases ≥ 80 years old. Cases who lived in areas with a high COVID-19 incidence demonstrated a longer reporting lag. Cases with a history of visiting a nightlife district also showed longer reporting lag than cases without such a history. Healthcare workers and cases with immunodeficiency both displayed shorter reporting lags than others.

Conclusion: Identifying newly infected cases as soon as possible and increased testing capacity for all age groups, and for individuals with a history of visiting high infection-risk areas, represented important measures in shortening reporting lags in the first wave period. The evidence from this study may provide lessons for controlling future emerging diseases.

1. Introduction

In December 2019, an outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections occurred in Wuhan, Hubei Province, China (Chen et al., 2020; Huang et al., 2020; Zhu et al., 2020), and spread across China and around the world. The World Health Organization declared the coronavirus disease 2019 (COVID-19) outbreak as a global pandemic on March 11, 2020 (Cucinotta and Vanelli, 2020). In Japan, the first case was confirmed on January 15, 2020. By the end of January 2020, 13 cases had been reported (MHLW, 2020a), including one case in Osaka Prefecture. On February 1, 2020, COVID-19 was added as a designated infectious disease under the Infectious Diseases Control Law in Japan, and doctors were required to report diagnosed COVID-19 cases to the public health center in their jurisdiction. Active epidemiological investigations have been underway since then. In the early phase of the first epidemic wave of COVID-19 in Osaka, lasting from February 17 to March 8, 2020, clusters relating to live entertainment events were reported in Osaka, resulting in 41 positive cases (Osaka Institute of Public Health et al., 2020). Containment of music event clusters in livehouses was achieved by detailed epidemiological investigations of cases and their contacts. Using analyses of early cases in Japan, the Japanese Ministry of Health, Labour, and Welfare (MHLW) found that most transmissions occurred through a small proportion of cases, often leading to clusters (i.e. superspreading events) (Nishiura et al., 2020). The MHLW therefore prioritized cluster investigation and backward contact tracing approaches to reduce the risk of transmissions (Jindai et al., 2020), and established the COVID-19 Cluster Response Taskforce on February 25, 2020 (Oshitani, 2020).

Well-implemented, fast, and effective contact tracing could offer important benefits in controlling and preventing outbreaks (Davis et al., 2021; Endo et al., 2021; Hellewell et al., 2020; Keeling et al., 2020; Kretzschmar et al., 2021). With regard to the effectiveness of contact tracing, a shorter 'reporting lag' – representing the time lag between symptom onset and a positive diagnosis/report – has a substantial impact in reducing onward transmissions (Baker et al., 2021; Hellewell et al., 2020; Kretzschmar et al., 2021, 2020). A longer lag contributes to a reduced probability of outbreak containment and an increased effective reproduction number. In Japan, a negative association between longer reporting lag and doubling time was reported using empirical data (Ogata and Tanaka, 2021). Keeping the reporting lag short plays an important role in preventing the transmission of diseases, and

* Correspondence: Takeshi Miyama, Division of Public Health, Osaka Institute of Public Health, 1-3-69 Nakamichi, Higashinari-ku, Osaka City, Osaka 537-0025, Japan.

E-mail addresses: miyama@iph.osaka.jp (T. Miyama), knkakimoto@iph.osaka.jp (K. Kakimoto), n-iritani@iph.osaka.jp (N. Iritani), motomura@iph.osaka.jp (K. Motomura).

https://doi.org/10.1016/j.ijregi.2022.06.002

Received 11 April 2022; Received in revised form 31 May 2022; Accepted 3 June 2022

2772-7076/© 2022 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
therefore identifying and understanding factors that influence reporting lag is crucial.

Cobre et al. (2020) investigated risk factors associated with delays in diagnosis, and found that male sex and living in low social development index areas (i.e., relating to economic, health, and educational levels) were risk factors for delays. In Japan, Ogata and Tanaka (2020) reported that cases with an unknown transmission link (i.e., the source from whom the individual had been infected) were associated with a longer reporting lag. However, the sample size used for data analysis was limited, since their study examined only a very early stage of the first wave in Japan. In addition, those results might have been influenced by regional situations, because measures enacted against this unprecedented pandemic varied among regions and countries from the beginning of the pandemic.

Our study was therefore conducted to investigate risk factors associated with reporting lag, using active epidemiological surveillance data from all symptomatic cases reported in Osaka Prefecture during the first wave of the COVID-19 epidemic (February 1–May 13, 2020). Another objective of this study was to gain an overview of experiences from Osaka Prefecture, and to provide evidence to support the control of future emerging diseases.

2. Methods

A cross-sectional study was conducted to identify risk factors for increased lag time between date of symptom onset and reporting.

2.1. Data source

Between February 1 and May 13, 2020, 1765 positive PCR tests for SARS-CoV-2 were reported in Osaka Prefecture. For these reported cases, positive epidemiological surveillance was conducted by the public health centers in Osaka Prefecture, and detailed information was collected. Among these cases, 1657 had information available on symptom onset date, 96 were asymptomatic, and 12 were unable to provide a date of symptom onset. The 1657 cases for whom date of symptom onset was available were used for this analysis.

The following factors were analyzed: date of symptom onset; date of report; age; sex; transmission link; residential area; history of visiting a nightlife district; employment as a healthcare worker; severe case; underlying disease (diabetes, heart disease, hypertonia, immunodeficiency, kidney disease, cancer, or asthma); number of newly infected cases in Osaka on the reporting date; total number of PCR tests for SARS-CoV-2 per day; and number of days since February 1, 2020 (the date on which the first case was reported in Osaka). Visiting a nightlife district, such as using host/hostess clubs, restaurants, and bars – i.e., closed environments and/or places where meals are consumed – is considered to be high-infection-risk behavior (Takaya et al., 2020; Liu et al., 2020; Nishihara et al., 2020). Daytime visits to these venues were also included, because some places are open during the day. Severity was defined at the time of reporting, and a severe condition was defined as requiring the use of critical care beds or any of an intensive care unit, ventilator, or extracorporeal membrane oxygenation (Osaka Prefecture, 2020).

Residential area information was missing for 24 cases from the study population of 1,657 cases. These 24 cases were therefore excluded from analyses.

2.2. Statistical analysis

2.2.1. Descriptive epidemiology

Mean, median, and interquartile ranges for reporting lag were calculated, and stratified by categories for the following factors: age (<10, 10s, 20s, 30s, 40s, 50s, 60s, 70s, and ≥80 years); transmission link (known/unknown); incidence rate in residential area (incidence rate levels 1–4, see below); history of visiting a nightlife district (yes/no); healthcare worker (yes/no); severe case (yes/no); and underlying disease conditions (yes/no). The incidence rate was calculated for each municipality as the number of positive PCR tests for the study period divided by the population. Interquartile ranges for incidence rate were assigned as four levels (low, middle, high, severe). The percentiles for the incidence rate per 100,000 were: 0th percentile, 4.92; 25th percentile,
9.26; 50th percentile, 16.00; 75th percentile, 19.11; 100th percentile, 30.47.

2.2.2. Risk factor analysis for time between date of symptom onset and reporting

To estimate the effects of factors (exposures) on reporting lag, multivariable regression models were built for each exposure variable to control for confounding effects, using generalized linear models. The following factors were set as exposure variables in the model that may have influenced reporting lag, and were considered biologically plausible: a) age; b) sex; c) transmission link; d) incidence rate in residential area; e) history of visiting a nightlife district; f) healthcare worker; g) severe case; h) underlying diabetes, heart disease, hypertension, immunodeficiency, kidney disease, cancer, or asthma; i) number of newly infected cases in Osaka; j) total number of PCR tests for SARS-CoV-2 per day on the reporting date; and k) number of days since February 1, 2020. The reporting lag was set as an outcome variable and it was assumed that a gamma distribution would be followed, referring to Akaike’s information criterion (AIC) values (Cobre et al., 2021) when fitted to Gaussian, Poisson, gamma, Weibull, and log-normal distributions (i.e. the AIC was lowest when fitting a gamma distribution). The calculated AICs are shown in Supplementary Table 1. Correlation coefficients among independent variables were calculated to check for multicollinearity (Dohoo et al., 2014). Covariates included in the model to control for confounding effects were selected based on the backdrop criteria (Morgan and Winship, 2015) by drawing causal diagrams using DAGitty (Textor, 2020) (Supplementary Figure 1).

3. Results

3.1. Descriptive epidemiology

The median reporting lag for the target population (1657 cases with information on date of symptom onset) was 8 days (mean: 8.6 days; interquartile range: 6–8 days). Reporting lag stratified by each factor is shown in Table 1. Age-dependent mean reporting lag was longest for individuals in their 30s (9.1 days) and shortest for individuals in their 10s (7.1 days). The reporting lags for individuals with unknown transmission link, living in a high-incidence-rate area for COVID-19, or with a history of visiting a nightlife district were longer than that for individuals without those factors. Healthcare workers, severe cases, and cases with an underlying comorbidity of heart disease, hypertension, immunodeficiency, kidney disease, or cancer showed shorter reporting lags compared with individuals without those factors. No significant differences were observed for the underlying disease condition of diabetes or for sex. Epidemic curves by date of symptom onset and by date of reporting for the study population (1657 symptomatic cases) are shown in Figure 1.

3.2. Risk factors for time between symptom onset and reporting

The estimated effects of exposures are shown in Table 2. No pairs of independent variables showed correlation coefficients > 0.9. The reporting lag for individuals in their 30s was 1.13 (95% CI 1.02–1.25) times longer than that for individuals ≥ 80 years. The reporting lag for those with a known transmission link was 0.84 (95% CI 0.81–0.89) times shorter than that for those with an unknown transmission link. Cases who lived in a high-COVID-19 incidence area showed a longer reporting lag (adjusted relative reporting lag 1.12; 95% CI 1.01–1.24) than cases who lived in an area with a low incidence rate. Cases who had a history of visiting a nightlife district showed a longer reporting lag (adjusted relative reporting lag 1.18; 95% CI 1.09–1.29) than cases who did not. Healthcare workers (adjusted relative reporting lag 0.79; 95% CI 0.73–0.85) and cases with immunodeficiency (adjusted relative reporting lag 0.70; 95% CI 0.55–0.90) had shorter reporting lags than individuals without those factors. The number of cases newly reported as positive PCR tests was negatively associated with reporting lag (adjusted relative reporting lag, 0.998; 95% CI 0.997–0.999). The full results for models, including covariates adjusted in the models, are shown in Supplementary Table 2 (i.e. the results for exposure variables only are shown in Table 2).

4. Discussion

For this study, the reporting lag was described using active epidemiological surveillance data for all symptomatic cases reported in Osaka Prefecture during the first wave of the COVID-19 epidemic (February 1–May 13, 2020). Factors associated with reporting lag were also quantitatively assessed in the first wave of the COVID-19 epidemic in Osaka.
Japan in order to provide an overview of our experiences. Cases in their 30s had a longer reporting lag than cases ≥ 80 years old. Cases who lived in an area with a high COVID-19 incidence rate had a longer reporting lag than cases who lived in an area with a low incidence rate. Cases who had a history of visiting a nightlife district had a longer reporting lag than cases who did not. The limited contact tracing and testing capacity could be one reason for a longer reporting lag. In the first wave of the COVID-19 epidemic in Japan, the limited capacity for testing meant that testing was prioritized for elderly and high-risk populations (e.g. individuals with comorbidities) (MHLW, 2020b). The limited

### Table 2
Estimated effects of exposures on time between symptom onset and report: results from multivariable analyses

| Factor                              | Relative reporting lag<sup>a</sup> (adjusted reporting lag for reference, days) | 95% CI – lower | 95% CI – upper | p-value | n  |
|-------------------------------------|---------------------------------------------------------------------------------|----------------|----------------|---------|----|
| **Age (years)**                     |                                                                                 |                |                |         |    |
| ≥ 80                                | Reference (8.10)                                                               | (7.45)         | (8.84)         |         | 1657|
| 70s                                 | 1.05                                                                            | 0.93           | 1.17           | 0.448   |    |
| 60s                                 | 1.03                                                                            | 0.92           | 1.16           | 0.628   |    |
| 50s                                 | 1.07                                                                            | 0.96           | 1.18           | 0.243   |    |
| 40s                                 | 1.05                                                                            | 0.95           | 1.17           | 0.331   |    |
| 30s                                 | 1.13                                                                            | 1.02           | 1.25           | 0.025   |    |
| 20s                                 | 1.08                                                                            | 0.97           | 1.19           | 0.153   |    |
| 10s                                 | 0.88                                                                            | 0.72           | 1.07           | 0.186   |    |
| < 10                                | 0.91                                                                            | 0.73           | 1.14           | 0.389   |    |
| **Sex**                             |                                                                                 |                |                |         | 1657|
| Female                              | Reference (8.59)                                                               | (8.28)         | (8.91)         |         |    |
| Male                                | 1.00                                                                            | 0.95           | 1.05           | 0.937   |    |
| **Transmission link**               |                                                                                 |                |                |         |    |
| Unknown                             | Reference (8.50)                                                               | (5.80)         | (8.75)         |         | 1633|
| Known                               | 0.84                                                                            | 0.81           | 0.90           | < 0.001 |    |
| **Residential area incidence rate** |                                                                                 |                |                |         |    |
| Low                                 | Reference (7.38)                                                               | (6.46)         | (8.46)         |         | 1633|
| Middle                              | 1.04                                                                            | 0.92           | 1.17           | 0.510   |    |
| High                                | 1.05                                                                            | 0.94           | 1.19           | 0.572   |    |
| Severe                              | 1.12                                                                            | 1.01           | 1.24           | 0.036   |    |
| **Visiting a nightlife district**   |                                                                                 |                |                |         |    |
| No                                  | Reference (7.51)                                                               | (6.57)         | (8.60)         |         | 1633|
| Yes                                 | 1.18                                                                            | 1.09           | 1.29           | < 0.001 |    |
| **Healthcare worker**               |                                                                                 |                |                |         |    |
| No                                  | Reference (7.51)                                                               | (6.58)         | (8.59)         |         | 1633|
| Yes                                 | 0.79                                                                            | 0.73           | 0.85           | < 0.001 |    |
| **Severe**                          |                                                                                 |                |                |         |    |
| No                                  | Reference (8.30)                                                               | (7.57)         | (9.14)         |         | 1657|
| Yes                                 | 0.92                                                                            | 0.84           | 1.02           | 0.119   |    |
| **Diabetes**                        |                                                                                 |                |                |         |    |
| No                                  | Reference (8.05)                                                               | (7.35)         | (8.83)         |         | 1657|
| Yes                                 | 1.04                                                                            | 0.94           | 1.15           | 0.425   |    |
| **Heart disease**                   |                                                                                 |                |                |         |    |
| No                                  | Reference (8.28)                                                               | (7.56)         | (9.08)         |         | 1657|
| Yes                                 | 0.89                                                                            | 0.79           | 1.01           | 0.061   |    |
| **Hypertonia**                      |                                                                                 |                |                |         |    |
| No                                  | Reference (8.17)                                                               | (7.48)         | (8.94)         |         | 1657|
| Yes                                 | 0.86                                                                            | 0.72           | 1.04           | 0.105   |    |
| **Immunodeficiency**                |                                                                                 |                |                |         |    |
| No                                  | Reference (8.13)                                                               | (7.45)         | (8.90)         |         | 1657|
| Yes                                 | 0.70                                                                            | 0.55           | 0.90           | 0.004   |    |
| **Kidney disease**                  |                                                                                 |                |                |         |    |
| No                                  | Reference (7.37)                                                               | (6.06)         | (9.08)         |         | 1657|
| Yes                                 | 0.83                                                                            | 0.70           | 1.01           | 0.051   |    |
| **Cancer**                          |                                                                                 |                |                |         |    |
| No                                  | Reference (7.37)                                                               | (6.06)         | (9.09)         |         | 1657|
| Yes                                 | 0.93                                                                            | 0.79           | 1.09           | 0.348   |    |
| **Asthma**                          |                                                                                 |                |                |         |    |
| No                                  | Reference (7.37)                                                               | (6.06)         | (9.08)         |         | 1657|
| Yes                                 | 1.11                                                                            | 0.97           | 1.29           | 0.136   |    |
| **Number of newly reported cases**  |                                                                                 |                |                |         |    |
| Intercept                           | Reference (7.60)                                                               | (6.66)         | (8.69)         |         | 1657|
| Slope                               | 0.998                                                                          | 0.997          | 0.999          | 0.001   |    |
| **Total number of PCR tests for SARS-CoV-2** |                                                               |                |                |         |    |
| Intercept                           | 7.96                                                                            | 6.84           | 9.27           |         | 1657|
| Slope                               | 1.0001                                                                         | 0.9998         | 1.0003         | 0.518   |    |
| **Number of days since February 1, 2020** |                                                               |                |                |         |    |
| Intercept                           | Reference (7.80)                                                               | (6.80)         | (8.95)         |         | 1657|
| Slope                               | 1.0013                                                                         | 0.9995         | 1.0030         | 0.178   |    |

---

<sup>a</sup> Reporting lag: time between symptom onset and report. <sup>b</sup>Interquartile levels of incidence rate were assigned as low, middle, high, or severe. <sup>c</sup>History of visiting a nightlife district. <sup>d</sup>Number of newly reported cases as positive PCR tests in Osaka on the day that a case was reported. <sup>e</sup>Total number of PCR tests for SARS-CoV-2 in Osaka per day on the date a case was reported. <sup>f</sup>February 1, 2020 was the date on which the first COVID-19 case was reported in Osaka.
ated capacity for contact tracing and testing might also have contributed to the longer time lag between symptom onset and testing for populations with high COVID-19 incidence, such as people in their 30s (16% of all cases observed), those in high-incidence residential areas, and those who visited nightlife districts. Our results revealed that cases for whom the transmission link was known had a shorter reporting lag than those for whom the transmission link was unknown. Generally, transmission links were detected by contact tracing. Since efficient contact tracing (including shorter reporting lag) acts to reduce COVID-19 transmissions (Baker et al., 2021; Hellewell et al., 2020; Kretzschmar et al., 2021, 2020), our study revealed that finding transmission links by contact tracing in Osaka Prefecture contributed to the control of the COVID-19 epidemic in Osaka. To shorten the reporting lag, our results suggested the following as crucial goals: a) identifying newly infected cases (regarding time, place, and person) as soon as possible by testing and contact tracing; b) increasing testing capacity for all age groups (specifically for those in their 30s) and for those with a history of visiting high-infection-risk areas (nightlife districts) or living in a high-incidence-rate residential area. Healthcare workers and cases with immunodeficiency had shorter reporting lags than cases without those factors. Although not statistically significant, cases with other comorbidities of the heart and kidney also tended to show a shorter reporting lag (p < 0.1). Infected healthcare workers were quickly identified as not transmitting the virus to others. Cases with immunodeficiency, heart, or kidney diseases, which represent high-risk factors for COVID-19 (Dessie and Zewotir, 2021; Williamson et al., 2020), were detected in a shorter time after symptom onset than others, indicating that high-risk groups were efficiently tested to avoid serious outcomes.

The number of newly reported cases was negatively associated with reporting lag. This result might indicate that detecting positive cases by contact tracing, which resulted in an increased number of reported cases, contributed to reducing reporting lag during the study period.

The results of this study must be viewed in consideration of several limitations. First, the estimated effects for reporting lag were not adjusted by possible confounders, such as accessibility of medical facilities and public health centers, or educational or income status. Second, underlying comorbidities other than immunodeficiency did not show significant results. The small sample sizes of groups with such comorbidities might have contributed to these results (diabetes, n = 134 cases; heart disease, n = 84; hypertension, n = 31; immunodeficiency, n = 17; kidney disease, n = 33; cancer, n = 44; asthma, n = 54). Third, our study did not assess how transmission settings (such as household, office, or welfare facility) influenced reporting lag among cases in which the transmission source was known. Finally, because the study period represented the very early phase of the pandemic, the laboratory testing system was not well prepared and the number of PCR tests was limited. The MHLW indicated that elderly individuals and those with an underlying comorbidity should consult public health centers earlier (MHLW, 2020b). Healthcare workers, hospitalized patients, the elderly, and workers in facilities for the elderly had higher priority for testing, based on decisions by public health centers. The capacity for testing varied among regions (according to expert opinions from the director of the regional public health center), and may have affected the incidence rates used for analysis.

In conclusion, risk factors associated with reporting lag in the early phase of the COVID-19 pandemic were quantitatively identified. Challenges that should be addressed to further minimize reporting lag were also discussed. The evidence from this study may provide lessons for controlling emerging diseases in Japan in the future.

Author contributions

TM: conceptualization, formal analysis, funding acquisition, investigation, methodology, visualization, writing – original draft; KK: data curation, investigation, methodology, validation, writing – review and editing; NI: investigation, interpretation, supervision, validation, writing – review and editing; KM: investigation, interpretation, supervision, validation, writing – review and editing

Acknowledgements

The authors would like to thank the public health centers in Osaka Prefecture and the Infectious Disease Control Support Division, Public Health and Medical Administration Office, Department of Public Health and Medical Affairs, Osaka Prefectural Government.

Funding

This work was supported by a Japan Society for the Promotion of Science (JSPS) Grant-in-Aid for Scientific Research (KAKENHI JP19K24219) to TM. The funder did not play any role in any of the following: study design; the collection, analysis, or interpretation of data; the writing of the report; or the decision to submit the article for publication.

Conflicts of interest

None

Ethical approval

This study was approved by the ethics committee of Osaka Institute of Public Health (application no. 2107-05-2). Personal identifiable information was not included in the dataset analyzed.

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.jiregi.2022.06.002.

References

Baker CM, Chades I, McVernon J, Robinson AP, Bondell H. Optimal allocation of PCR tests to minimise disease transmission through contact tracing and quarantine. Epidemics 2021;37, doi:10.1016/J.EPIDEM.2021.100503.

Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395:507–13. doi:10.1016/S0140-6736(20)30211-7.

Cobre A de F, Böger R, Fachi MM, Vilhena R de O, Domingos EL, Tonin FS, et al. Risk factors associated with delay in diagnosis and mortality in patients with COVID-19 in the city of Rio de Janeiro, Brazil. Cien Saude Colet 2020;25:4131–40. doi:10.1590/1413-812320202510.2.26882020.

Cobre AF, Surek M, Vilhena RG, Böger R, Fachi MM, Momade DR, et al. Influence of foods and nutrients on COVID-19 recovery: a multivariate analysis of data from 170 countries, using a generalized linear model. Clin Nutr 2021. doi:10.1016/J.CLINU.2021.05.018.

Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Bio Med Atenei Parm 2020;91:157. doi:10.23750/ABM.V91I1.9397.

Davis EL, Lucas TCD, Bolorase A, Pollington TM, Abbott S, Ayabina D, et al. Contact tracing is an imperfect tool for controlling COVID-19 transmission and relies on population adherence. Nat Commun 2021;12:1–8. doi:10.1038/s41467-021-25531-5.

Dessie ZG, Zewotir T. Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients. BMC Infect Dis 2021:21:1–28. doi:10.1186/s12879-021-06536-3 FIGURES 10.

Dohoo IR, Martin SW, Stryhn H. Model building strategies. Veterinary epidemiologic research. Charlottetown: VER Inc; 2014. p. 365–94.

Endo A, Leclerc QJ, Knight GM, Medley GF, Atkins KE, Funk S, et al. Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreaks. Wellcome Open Res 2021;5:1–17. doi:10.12688/WELLCOMERES.16344.3.

Hellewell J, Abbott S, Gimma A, Bosse N, Jarvis CI, Russell TW, et al. Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts. Lancet Glob Heal 2020;8:e888–96. doi:10.1016/S2214-109X(20)30074-7.

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506. doi:10.1016/S0140-6736(20)30183-5 ATTACHMENT/D3532CA1-8208-4CA4-BC97-00A390BF3096/AMC1.PDF.

Jindal K, Furuse Y, Oshitani H. Cluster-based approach to COVID-19 response in Japan (Japanese). Infect Agents Survell Rep 2020;41:108-10.
Ogata, T., Tanaka, H. High probability of long diagnostic delay in coronavirus disease 2019 cases with unknown transmission route in Japan. Int J Environ Res Public Health 2020;17:1–9. doi:10.3390/ijerph17228655.

Osaka Institute of Public Health, Osaka Prefecture, Osaka City Health Care Center. COVID-19 epidemic in Osaka Prefecture. Infect Agents Surveill Rep 2020;41:110–11. Osaka Prefecture. The 29th Osaka Prefecture COVID-19 response headquarters meeting. https://www.pref.osaka.lg.jp/attach/38215/00379293/ikkatsu.pdf, 2020 (accessed November 12, 2021).

Oshitani H. Cluster-based approach to coronavirus disease 2019 (COVID-19) response in Japan, from February to April 2020. Jpn J Infect Dis 2020;73:491–3. doi:10.7883/yoken.JJID.2020.363.

Takaya S, Tsuruki S, Hayakawa K, Kawashima A, Okuhama A, Kanda K, et al. Nightlife clusters of coronavirus disease in Tokyo between March and April 2020. Epidemiol Infect 2020b;148:e250. doi:10.1017/S0950268820002496.

Textor J. Drawing and analyzing causal DAGs with DAGitty. http://dagitty.net/, 2020 (accessed January 15, 2022).

Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nat 2020;584:430–6. https://doi.org/10.1038/s41586-020-2521-4.

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382:727–33. doi:10.1056/NEJMoa2001017.

Keeling MJ, Hollingsworth TD, Read JM. Efficacy of contact tracing for the containment of the 2019 novel coronavirus (COVID-19). J Epidemiol Community Health 2020;74:861–6. doi:10.1136/jech-2020-214051.

Kretzschmar ME, Rohnova G, Bootsma MCJ, van Boven M, van de Wijgerd JHJM, Bonten MJM. Impact of delays on effectiveness of contact tracing strategies for COVID-19: a modelling study. Lancet Public Health 2020;5:e452–9. doi:10.1016/S2468-2667(20)30157-2/ATTACHMENT/B3B417B1-0A5E-4E37-8EDC-3BDC0246F819/MMC1.PDF.

Kretzschmar ME, Rohnova G, van Boven M. Isolation and contact tracing can tip the scale to containment of COVID-19 in populations with social distancing. Front Phys 2021;9:677. doi:10.3389/fphy.2020.622485/BIBTEX.